Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699139 | 0.91 | EIF4A3 (0.34) | EIF4A3PDE2AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL24868582 | 0.87 | EIF4A3 (0.34) | EIF4A3PDE2AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL12067546 | 0.84 | DPP4 (0.34) | KDM4EALDH1A1CYP1A2MAPTALOX15 | |
| SCHEMBL13676942 | 0.83 | PDE2A (0.39) | EIF4A3PDE2A | |
| SCHEMBL16736781 | 0.82 | ALOX15 (0.46) | KDM4EALDH1A1CYP1A2MAPTALOX15 | |
| SCHEMBL19170652 | 0.82 | PTGS2 (0.35) | PDE2ASMN1; SMN2 | |
| SCHEMBL16736902 | 0.82 | ALOX15 (0.52) | EIF4A3KDM4EALDH1A1CYP1A2MAPT | |
| SCHEMBL12173270 | 0.81 | EIF4A3 (0.42) | EIF4A3PDE2ACYP1A2 | |
| SCHEMBL13945794 | 0.81 | ALDH1A1 (0.43) | KDM4EALDH1A1CYP1A2MAPTALOX15 | |
| SCHEMBL21139123 | 0.79 | CYP2C9 (0.38) | ALDH1A1CYP1A2ALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-11220490-B2 | Ureas having androgen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210300901-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300901-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | EIF4A3 2307/4885PDE2A 1125/4885KDM4E 1268/4885 |
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | EIF4A3 3700/4885PDE2A 304/4885KDM4E 4593/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | EIF4A3 2476/4885PDE2A 3940/4885KDM4E 4052/4885 |
| US-11220490-B2 | Ureas having androgen receptor degradation activity and uses thereof | AR, UTS2R, ESRRA | EIF4A3 2462/4885PDE2A 1324/4885KDM4E 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.